RNA, U6 small nuclear 658, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-658P profile across patient tissues and cancer cell-line models. RNU6-658P expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, RNU6-658P is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, RNU6-658P RNA expression shows 17,231 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BRCA, KICH, and THYM as cancer lineages where RNU6-658P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-658P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-658P survival associations across molecular data types. RNU6-658P RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-658P RNA expression–survival associations across cancer types. High RNU6-658P expression shows unfavorable associations in LIHC, UVM, COAD and THCA, but favorable associations in BRCA and UCS. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for RNU6-658P RNA expression.
This table summarizes RNU6-658P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-658P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-658P shows higher tumor expression in KICH, CHOL, BLCA, COAD, KIRC and UCEC. The KICH box plot shows higher RNU6-658P RNA expression in tumor versus normal tissue (log2 FC = +1.049, t-test p = .001).
This table shows molecular features associated with RNU6-658P in patient tissues and cancer cell lines. In patient samples, RNU6-658P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
